Harnessing Proteomics: The ProVue Lung Test for Early Lung Cancer Detection

PrognomiQ launched ProVue Lung, a proteomics-based laboratory-developed test intended to detect protein biomarkers of early-stage lung cancer in high-risk patients.

The assay profiles multiple protein signals from patient samples and converts them into a composite risk score to flag early molecular disease. The test is positioned to augment existing low-dose CT screening pathways as an adjunct triage and risk-stratification tool for high‑risk populations.

Relative to imaging-based screening and single-marker assays, ProVue Lung brings multi-protein signature analysis earlier in the screening pathway and alongside established low-dose CT programs. Unlike single-analyte tests that interrogate one pathway, a multi-analyte proteomic approach evaluates broader tumor-associated biology and may increase sensitivity for small-volume, early disease—though prospective clinical performance data are needed. Its most pragmatic role at launch is likely adjunctive: refining triage for indeterminate imaging findings and stratifying risk within screening cohorts.

Proteomics identifies distinctive protein signatures by profiling tumor-related proteomes and distinguishing patterns linked to early malignant change. Defined protein panels can help separate early-stage disease from benign processes at the molecular level, supporting both population-level screening refinement and individualized risk assessment. The test’s mechanistic contribution is therefore pattern recognition across multiple protein signals, pending prospective validation to confirm clinical performance.

This launch signals immediate operational priorities: prospective validation in clinical cohorts, linkage with existing screening programs, and workflow integration to ensure timely reporting. Comparative performance data versus current standards and prospective accuracy studies are necessary to establish clinical utility.

Going forward, ProVue Lung creates a pathway to layer proteomic risk stratification into early-detection programs and to inform subsequent research and implementation efforts.

Key Takeaways:

• A proteomics-based LDT offering a multi-protein risk score to support earlier detection workflows.
• Patients with indeterminate low-dose CT findings and individuals meeting high‑risk screening criteria—both groups may benefit from refined triage.
• Laboratory integration, timely result reporting, and prospective validation within local screening programs are needed before routine clinical adoption.